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A wide variety of agents activate AMPK, but in many
cases the mechanisms remain unclear. We gener-
ated isogenic cell lines stably expressing AMPK
complexes containing AMP-sensitive (wild-type,WT)
or AMP-insensitive (R531G) g2 variants. Mitochon-
drial poisons such as oligomycin and dinitrophenol
only activated AMPK inWT cells, as did AICAR, 2-de-
oxyglucose, hydrogen peroxide,metformin, phenfor-
min, galegine, troglitazone, phenobarbital, resvera-
trol, and berberine. Excluding AICAR, all of these
also inhibited cellular energy metabolism, shown by
increases in ADP:ATP ratio and/or by decreases in
cellular oxygen uptake measured using an extracel-
lular flux analyzer. By contrast, A769662, the Ca2+
ionophore, A23187, osmotic stress, and quercetin
activated both variants to varying extents. A23187
and osmotic stress also increased cytoplasmic
Ca2+, and their effects were inhibited by STO609,
a CaMKK inhibitor. Our approaches distinguish at
least six different mechanisms for AMPK activation
and confirm that the widely used antidiabetic drug
metformin activates AMPK by inhibiting mitochon-
drial respiration.
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a sensor of cellular
energy status comprising heterotrimers formed from a catalytic
a subunit that is only active after phosphorylation at Thr-172
by upstream kinases, and regulatory (b and g) subunits (Hardie,
2007). There are several alternative upstream kinases in mam-
mals, including the tumor suppressor LKB1 (Hawley et al.,
2003; Woods et al., 2003) and the calmodulin-dependent kinase
kinases CaMKK-a and -b (Hawley et al., 2005; Hurley et al., 2005;
Woods et al., 2005). Any cellular stress that depletes cellular ATP
and increases the ADP:ATP ratio causes, via adenylate kinase,
a much larger increase in the AMP:ATP ratio. AMP binding stim-
ulates AMPK by two mechanisms: (1) allosteric activation of
phosphorylated AMPK, and (2) inhibition of dephosphorylation
of Thr-172 by protein phosphatases (Davies et al., 1995; Suter
et al., 2006; Sanders et al., 2007b). Both effects are caused by554 Cell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc.binding of AMP at two exchangeable sites on the g subunits
and are opposed by ATP, which binds at the same sites (Scott
et al., 2004; Xiao et al., 2007). LKB1 provides a high basal
Thr-172 phosphorylation, against which the inhibitory effect of
AMP on dephosphorylation can operate. Activation of CaMKKs
by Ca2+/calmodulin provides an alternate pathway by which
AMPK can be activated by increasing intracellular Ca2+ levels,
independently of AMP.
Once activated, AMPK switches on catabolic pathways that
generate ATP, while switching off ATP-requiring processes not
essential for short-term cell survival, including cell growth and
proliferation (Hardie, 2007). Numerous stresses activate AMPK,
including treatment with heat shock or metabolic poisons
(Corton et al., 1994), muscle contraction (Winder and Hardie,
1996), glucose deprivation (Salt et al., 1998), hypoxia (Evans
et al., 2005), oxidative stress (Choi et al., 2001), and osmotic
stress (Fryer et al., 2002). AMPK is also regulated by cytokines
involved in regulating whole-body energy balance (Kahn et al.,
2005). In addition, a bewildering variety of drugs and xenobiotics
has been found to activate AMPK, including (1) A-769662, devel-
oped by Abbott laboratories (Cool et al., 2006); (2) the antidia-
betic biguanides, metformin (Zhou et al., 2001) and phenformin
(Hawley et al., 2003), and a related natural product, galegine
(Mooney et al., 2008); (3) another class of antidiabetic drug, the
thiazolidinediones, (Fryer et al., 2002); (4) the barbiturate, pheno-
barbital (Rencurel et al., 2005); and (5) phytochemicals derived
from traditional medicines, such as berberine (Lee et al., 2006),
or present in foods or beverages, such as quercetin (Ahn et al.,
2008; Suchankova et al., 2009), resveratrol (Baur et al., 2006),
genistein, capsaicin, and epigallocatechin gallate (Choi et al.,
2001; Hwang et al., 2005).
It is a challenge to understand how such a variety of compounds
with different structures all lead to AMPK activation, and various
suggestions have been made. Biguanides (El-Mir et al., 2000;
Owen et al., 2000) and thiazolidinediones (Brunmair et al., 2004)
are inhibitors of complex 1 of the respiratory chain, indicating
that they might activate AMPK via inhibition of ATP synthesis
and consequent increases in AMP. However, while thiazolidine-
diones (Fryer et al., 2002; Lebrasseur et al., 2006) and phenformin
(Hawley et al., 2005) have been reported to alter adenine nucleo-
tide ratios in cultured cells, activation by metformin was seen
under conditions where no such changes were detectable (Fryer
et al., 2002; Hawley et al., 2002). Similarly, osmotic stress (Fryer
et al., 2002), hydrogen peroxide (Choi et al., 2001), and resveratrol
(Suchankova et al., 2009) have been claimed to activate AMPK
without any change in cellular nucleotides.
Figure 1. Analysis of HEK293 Cells Stably Expressing WT g2 and the
R531G Mutant
(A) Duplicate western blots of parental HEK293 cells and WT or RG cells using
antibodies against the a1, a2, b1, b2, g1, and g2 subunits of AMPK, and
against the FLAG epitope on g2.
(B) AMPK activities in parental HEK293 cells and WT and RG cells, in samples
made by immunoprecipitation using anti-FLAG antibodies, and by subsequent
immunoprecipitation from the anti-FLAG supernatants using anti-a1/a2 anti-
bodies. Results (mean ± SD, n = 2) are expressed as units per milligram of
protein in the volume of cell lysate from which the first immunoprecipitation
was performed.
(C) Effect of AMP (200 mM) and A769662 (1 mM) in cell-free assays of anti-FLAG
immunoprecipitates from WT and RG cells. Results expressed as in (B). Signif-
icant differences between indicated groups were determined by one-way
ANOVA (***p < 0.001; n.s., not significant).
(D) Western blots (n = 4) showing phosphorylation (pT172) and expression
(a1/a2) of AMPK, phosphorylation (pACC) and expression (ACC) of acetyl-
CoA carboxylase, and expression of three mitochondrial markers (cyt c, cyto-
chrome c; cox2, flavoprotein subunit of succinate dehydrogenase [SDHA];
cox5, ATP synthase, F1 complex, b subunit) in WT and RG cells.
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AMP (Hardie et al., 1999; Suter et al., 2006), and it seemed to us
that it might be activated by subtle changes in cellular nucleo-
tides that may not be detectable by measuring total cellular
levels. Adenine nucleotides are compartmentalized between
the mitochondria and cytoplasm and, due to limitations on diffu-
sion, may not be uniformly distributed even within the cytoplasm
(Dzeja and Terzic, 2003). Cellular concentrations of ADP and
AMP are usually too low to be measured directly by 31P NMR;
their contents can be estimated in cell extracts, but in that
case effects of compartmentation will be lost. Therefore, while
an agent like metformin may activate AMPK without producing
a detectable change in adenine nucleotides, this does not prove
that the effect is AMP independent. We felt that it was important
to develop a more sensitive diagnostic test to determine whether
or not activation of AMPK by different agents was AMP depen-
dent. The recent discovery of mutations that render the AMPK
complex AMP insensitive provided an opportunity to achieve
this. Point mutations in the g2 subunit are associated with ele-
vated glycogen in cardiac myocytes, leading to cardiac arrhyth-
mias and hypertrophy (Arad et al., 2007). These mutations inter-
fere with the binding of the regulatory nucleotides, AMP and
ATP, to two sites on the g subunit (Scott et al., 2004; Xiao
et al., 2007). For the present study, we have selected one of
these mutations, R531G, that causes a severe loss of binding
of AMP and ATP, thus generating an AMP-insensitive complex
(Scott et al., 2004). We constructed isogenic HEK293 cells stably
expressing either wild-type g2 or this mutant and used them to
test whether a variety of pharmacological agents and stresses
that activate AMPK do so via increases in AMP.
RESULTS
Characterization of Stably Transfected Cells
We generated stable, isogenic HEK293 lines expressing the WT
or the R531G mutant using the Flp-In system, in which the DNA is
inserted by homologous recombination into a single Flp recom-
bination target (FRT) site previously introduced into the host
cells. The a, b, and g subunits of AMPK are unstable when
expressed individually in cells, and coexpression of all three is
necessary to obtain significant overexpression. We therefore
suspected that if we stably expressed only the g2 subunit, it
might replace the endogenous g1 subunit in the HEK293 cells,
a hypothesis supported by the data in Figure 1. By Western blot-
ting (Figure 1A), the expression of the a1, a2, b1, and b2 subunits
was not significantly altered in cells stably expressing wild-type
g2 (referred to below as WT cells) or the R531G mutant (RG
cells), compared with the parental cells containing the FRT
site. As expected, g2 was readily detectable by Western blotting
in the WT and RG cells, using either anti-g2 or anti-FLAG anti-
bodies. However, expression of the endogenous g1 subunit
decreased markedly, suggesting that the recombinant g2 had
largely, if not entirely, replaced it. This was confirmed by another
approach (Figure 1B). When cell extracts were immunoprecipi-
tated with anti-FLAG antibodies, the activity recovered from
the parental cells was negligible as expected, but immunopre-
cipitation from the resulting supernatant using anti-a subunit
antibodies yielded a substantial activity, corresponding to the
endogenous AMPK complexes containing g1. If the same exper-Ciments were carried out with WT or RG cells, activities 2- to 3-fold
higher than the endogenous activity of the parental cells
(measured in the presence of AMP) were recovered using anti-
FLAG antibody, but the activity recovered from the subsequent
immunoprecipitate using anti-a antibodies was reduced by >
80%. These results show that the recombinant FLAG-tagged
g2 subunit had largely replaced the endogenous g1 subunit
within AMPK complexes in the WT and RG cells.
We next examined the effects of AMP and A769662 in cell-free
assays of AMPK recovered using anti-FLAG antibodies from WT
and RG cells. AMPK from WT cells was activated 3-fold by AMP
and 2-fold by A769662 (Figure 1C). As expected, AMPK from RG
cells was not activated by AMP, but it was still stimulated by
A769662, consistent with previous results (Sanders et al.,
2007a) showing that the equivalent R298G mutation in g1 did
not affect activation by A769662. Another notable finding inell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc. 555
Figure 2. ConcentrationDependence of AMPKActivation by Various
Agents
Results are shown for WT cells (open circles) or RG cells (filled circles). Incu-
bations with the indicated agent were for 1 hr, after which AMPK was immuno-
precipitated using anti-FLAG antibody and assayed at 200 mM AMP. Results
(mean ± SD, n = 2) are expressed as percentages of the activity in controls
without added agent.
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AMP) of the R531G mutant was 2-fold higher (p < 0.001) than that
in the WT cells. This increased activity correlated with a 2-fold
higher level of phosphorylation of AMPK at Thr-172 (pT172,
p < 0.001), and a 2.6-fold increase in phosphorylation of
acetyl-CoA carboxylase (pACC, p < 0.0001), with no change in
expression of either protein (Figure 1D).
Effects of Metabolic Stresses and AMPK Activators
We next tested on WT and RG cells various agents previously
shown to activate AMPK (Figure 2). Oligomycin (an inhibitor of
the mitochondrial ATP synthase), dinitrophenol (DNP, which
uncouples the respiratory chain from ATP synthesis), 2-deoxy-
glucose (an inhibitor of glycolysis), 5-aminoimidazole-4-carbox-
amide riboside (AICAR, a nucleoside converted within the cell to
an AMP mimetic), and the reactive oxygen species, hydrogen
peroxide, all activated AMPK in WT cells but had no effect in
RG cells. By contrast, the effects of osmotic stress (induced by
the cell-impermeant solute, sorbitol) and increasing cytoplasmic
calcium using the Ca2+ ionophore, A23187, were reduced but
not abolished in RG cells. Finally, activation by A769662 was
completely unaffected by the RG mutation. These latter results
provide important positive controls, because they show that
the RG mutant, although insensitive to AMP, is nevertheless
functional and can still be activated by treatments that do not
involve a change in cellular AMP.
Effects of Other AMPK-Activating Drugs
We next tested the effects of a variety of drugs and xenobiotics
that have been reported to activate AMPK in cell-based assays
(Figure 3). First, we studied biguanides currently or previously
used to treat type 2 diabetes, i.e., metformin and phenformin.
Metformin uptake in HEK293 cells is very slow due to lack of
expression of the transporter OCT1 (Shu et al., 2007), so incuba-
tion with metformin was for 16 hr rather than the 1 hr incubation
used for all other treatments. Nevertheless, metformin and phen-
formin, as well as the related natural product galegine (isoprenyl
guanidine), clearly activated AMPK in WT cells, but not RG cells.
Similar results were obtained with the thiazolidinedione, troglita-
zone, and the barbiturate, phenobarbital. Finally, we studied
quercetin (a plant flavonoid), resveratrol (a polyphenol present
in red wine), and berberine (from the genus Berberis, used in
traditional Chinese medicine). All three agents caused a robust
activation of AMPK in WT cells. Resveratrol and berberine had
no effect in RG cells, although a modest effect did remain with
quercetin.
Phosphorylation of AMPK
The assays in Figures 2 and 3 were conducted in immunoprecip-
itates at saturating AMP concentration (200 mM), suggesting that
the effects were due to increased phosphorylation rather than
allosteric activation. Confirming this, there was a good correla-
tion between increased AMPK activation and Thr-172 phosphor-
ylation assessed by Western blotting. Thus, all 16 treatments
produced clear increases in Thr-172 phosphorylation in WT cells
without any changes in a1/a2 subunit expression (Figure 4). With
oligomycin, DNP, 2-deoxyglucose, AICAR, hydrogen peroxide,
metformin, phenformin, galegine, troglitazone, phenobarbital,
resveratrol, and berberine, this was only observed in WT but556 Cell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc.not RG cells, while with sorbitol, A23187, A769662, and
quercetin there was also increased Thr-172 phosphorylation in
RG cells.
Changes in Cellular Nucleotides
If treatments that activate AMPK in WT but not RG cells do so
because they increase cellular AMP, they would be predicted
Figure 3. Concentration Dependence of AMPK Activation by the
Indicated Drugs and Phytochemicals
Results are shown for WT cells (open circles) or RG cells (filled circles). Incu-
bations with the indicated agent were for 1 hr (except metformin, 16 hr), after
which AMPK was assayed as for Figure 2. Results (mean ± SD, n = 2 except
quercetin, n = 4) are expressed as percentages of the activity in controls
without added agent.
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capillary electrophoresis to measure nucleotides in perchloric
acid extracts. While AMP could usually be detected in treated
cells (data not shown), its content was too low to reliably esti-
mate in the untreated cells. To obtain a quantitative measure of
energy stress, we therefore measured the ADP:ATP ratio and
used it as a surrogate for AMP:ATP (which, assuming that adeny-Clate kinase reaction is at equilibrium, will vary as the square of
ADP:ATP [Hardie and Hawley, 2001]). As expected, the mito-
chondrial inhibitors oligomycin and DNP, and the glycolytic
inhibitor 2-deoxyglucose, all increased the ADP:ATP ratio in
WT cells (Figure 5A), whereas AICAR, A23187, and A769662
did not produce a significant change. Hydrogen peroxide
increased the ADP:ATP ratio significantly in WT cells at 0.3 mM
and to a much greater extent (15-fold, data not shown) at
1 mM. Osmotic stress using sorbitol also caused a small
increase in ADP:ATP in both WT and RG cells.
Results with a wide range of AMPK-activating drugs and xeno-
biotics are shown in Figure 5B. Although metformin appeared to
cause small increases in ADP:ATP (16% in WT and 38% in RG
cells), these were not statistically significant. All other drugs
produced significant increases, both in WT and RG cells. The
effect of 100 mM quercetin was small but significant (1.6-fold,
Figure 5B), while the effect of 300 mM quercetin (data not shown)
was much larger (18-fold in WT and 33-fold in RG cells).
Interestingly, with the exceptions of 2-deoxyglucose, quer-
cetin, and resveratrol, the agents that caused increases in the
ADP:ATP ratio tended to cause larger increases in the WT than
in the RG cells, suggesting that the latter might be more resistant
to metabolic stress. Since AMPK has been found to promote
mitochondrial biogenesis, we initially hypothesized that the
higher basal AMPK activity in the RG cells (Figure 1) meant
that they might have higher mitochondrial content and thus a
greater capacity to generate ATP. However, this appears not
to be the case. First, expression of a number of mitochondrial
markers (cyt c, cox2, cox5) was not different between the WT
and RG cells (Figure 1D). Second, the density of mitochondria
by fluorescence microscopy of cells stained with MitoTracker
dye was not different (data not shown). Third, the rate of oxygen
uptake in WT and RG cells, when maximally stimulated using
DNP, was not significantly different (see next section).
Most Treatments that Increase AMP Inhibit O2 Uptake
To confirm that most treatments that activate AMPK in a strictly
AMP-dependent manner act by inhibiting mitochondrial metab-
olism, we analyzed their effects on oxygen uptake using an
extracellular flux analyzer. Basal oxygen uptake was very similar
between the two cell lines (WT, 4.6 ± 1.3 [mean ± SD, n = 38];
RG, 4.3 ± 0.8 [n = 31] nmol/min/106 cells). If the cells were titrated
with an inhibitor of the ATP synthase, oligomycin, oxygen uptake
in the WT cells decreased by a maximum of 60% to 1.8 ± 0.4
(WT, n = 7) and 1.6 ± 0.2 (RG, n = 8) nmol/min/106 cells. If the cells
were titrated with the uncoupler DNP, basal oxygen uptake in the
WT cells increased by a maximum ofz3-fold to 15.4 ± 2.1 (WT,
n = 5) and 13.7 ± 2.3 (RG, n = 8) nmol/min/106 cells. The rates in
the presence of DNP represent estimates of the maximal rate of
the respiratory chain. Neither the basal, the oligomycin-inhibited,
nor the DNP-stimulated rates were significantly different
between the WT and RG cells, confirming that the mitochondrial
capacities of these cells were similar.
All stress and drug treatments also had very similar effects on
oxygen uptake in WT cells (Figures 6A and 6B) and in RG cells
(see Figure S1 available online). Hydrogen peroxide, phenformin,
galegine, troglitazone, Phenobarbital, and berberine all inhibited
basal oxygen uptake in a similar manner, and in these cases
there was no significant stimulation of oxygen uptake onell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc. 557
Figure 4. Phosphorylation of Thr-172 on
AMPK-a in WT or RG Cells in Response to
Various Agents
Cells were incubated in duplicate for 1 hr (except
metformin, 16 hr) with the indicated agent at the
following concentrations: oligomycin (1 mM), DNP
(100 mM), 2-deoxyglucose (30 mM), AICAR (3 mM),
hydrogen peroxide (1 mM), sorbitol (1.5 M),
A23187 (3 mM), A769662 (300 mM), metformin
(3 mM), phenformin (3 mM), galegine (100 mM), tro-
glitazone (100 mM), phenobarbital (3 mM), quer-
cetin (100 mM), resveratrol (300 mM), and berberine
(100 mM).
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the respiratory chain. Osmotic stress also reduced oxygen
uptake; subsequent addition of DNP increased the rate slightly,
but not to the level seen after oligomycin. Resveratrol and quer-
cetin inhibited basal oxygen uptake, although with quercetin
inhibition was not significant at 100 mM and was only modest
(25%, Figure 6 and Figure S1) at 300 mM. With these agents there
was a large stimulation in oxygen uptake after subsequent addi-
tion of DNP, although with resveratrol this did not reach the level
seen after oligomycin or quercetin. 2-deoxyglucose, AICAR,
A23187, and A769662 produced no changes either in basal or
DNP-stimulated oxygen uptake.
Metformin appeared to produce an almost total inhibition of
oxygen uptake with no subsequent stimulation by DNP (Fig-
ure 6B). However, because of the slow uptake of metformin by
HEK293 cells, the incubation with metformin was for 16 hr rather
than 1 hr as for other treatments. Due to the long incubation we
were also forced to use a different experimental design in which558 Cell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc.the basal and metformin-inhibited rates
were measured in different wells on the
same plate, rather than in the same wells
before and after addition of the drug as
for other treatments. To circumvent the
problem of the slow uptake of metformin
by HEK293 cells, we also studied H4IIE
cells, a rat hepatoma cell line that we sus-
pected might express the organic cation
tranporter OCT1, which promotes met-
formin uptake (Shu et al., 2007). In these
cells, activation of endogenous AMPK
by metformin was much more rapid,
reaching a maximum after 2–3 hr with
a half-maximal effect at 1.1 mM (data
not shown), consistent with a reported
Km of OCT1 for metformin of 1.5 mM
(Koepsell et al., 2007). To confirm that
the more rapid effect of metformin in
H4IIE cells was due to the expression of
OCT1, we investigated the effects of
quinidine, a high-affinity substrate for
OCT1 that acts as a competitive inhibitor.
As expected, in H4IIE cells quinidine
almost completely blocked AMPK activa-
tion, as well as the phosphorylation ofthe AMPK target, ACC, by metformin. By contrast, quinidine
had no effect on the responses to phenformin or galegine (Fig-
ure 6C). Figure 6D shows that, after a lag of about 30 min, met-
formin caused a time- and concentration-dependent decrease
of oxygen uptake in H4IIE cells. At 10 mM metformin, inhibition
of oxygen uptake was significant by 45 min and had reached >
80% by 2 hr. After this, addition of a maximally effective concen-
tration of the uncoupler DNP caused only a modest stimulation of
oxygen uptake, consistent with the idea that metformin was
inhibiting the respiratory chain.Effect of STO-609 and Ca2+ Measurements
To examine whether activation of AMPK by agents that acted in
an AMP-independent manner required calmodulin-dependent
protein kinase kinases (CaMKKs), we utilized the CaMKK inhib-
itor, STO-609 (Figure 7A). As expected, increasing concentra-
tions (3 and 10 mM) of the Ca2+ ionophore A23187 progressively
Figure 5. Effect of Indicated Treatments on ADP:ATPRatios inWTor
RG Cells
Cells were incubated for 1 hr (except metformin, 16 hr) with the indicated agent
at concentrations used in Figure 4. Contents of ATP and ADP in perchloric acid
extracts were estimated using capillary electrophoresis and are expressed as
a ratio. Results are mean ± SD (n = 16 for controls; n = 2 for all others). Means
that are significantly different by one-way ANOVA from controls performed
at the same time without treatment are indicated: *p < 0.05, **p < 0.01,
***p < 0.001. Abbreviations: DNP, dinitrophenol; 2-DG, 2-deoxyglucose.
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was completely blocked by STO-609. The results were essen-
tially identical with WT or RG cells. The effects of osmotic stress
using sorbitol were also inhibited significantly, but not com-
pletely, by STO-609 in both cell types (Figure 7B), suggesting
that in this case the effect is only partially mediated by CaMKKs.
As expected, STO-609 did not inhibit activation of AMPK by
berberine or A769662 (Figures 7C and 7D).
We also compared the effects of A23187, sorbitol, and ber-
berine on cytoplasmic Ca2+ concentration assessed using the
Ca2+-sensitive fluorescent dye, fura-2. Example time courses
in individual WT cells are shown in Figure 7E, while results of
several experiments in WT and RG cells are summarized in
Figure 7F. Within 1 min of addition, A23187 and sorbitol pro-
duced large but transient increases in intracellular Ca2+ in both
WT and RG cells. The Ca2+ levels then declined to a level that
remained above the baseline for at least 8 min. There was no
detectable change in intracellular Ca2+ concentration during
incubation for up to 10 min following addition of 30 mM berberine,
in either cell line (n = 6).CDISCUSSION
Our stable cell lines expressing the wild-type and R531G mutant
versions of g2 provide a sensitive assay to test whether agents
that activate AMPK do so via AMP-dependent or AMP-indepen-
dent mechanisms. A769662 (a direct AMPK activator unaffected
by the R531G mutation) and the Ca2+ ionophore A23187 (which
increases cytoplasmic Ca2+ and thus activates the upstream
kinase, CaMKKb) caused increased phosphorylation and activa-
tion of AMPK in both WT and RG cells, showing that the R531G
mutant is still capable of being activated, and providing impor-
tant positive controls. Neither AICAR, A23187, nor A769662
had any effect on ADP:ATP ratios or basal or DNP-stimulated
oxygen uptake in WT or RG cells, confirming that they do not
inhibit mitochondrial metabolism. AICAR also failed to cause
activation or phosphorylation of the R531G mutant, but this is
consistent with previous studies showing that ZMP (the AMP
mimetic formed by intracellular metabolism of AICAR) binds to
the AMPK g subunits in a similar manner to AMP (Day et al.,
2007).
With the above exceptions (as well as 2-deoxyglucose, which
inhibits glycolysis) we found that most compounds tested inhibit
mitochondrial ATP production and thus activate AMPK indirectly
by altering cellular AMP:ATP ratios. This included the classical
mitochondrial inhibitors oligomycin and DNP; the guanidine
derivatives metformin, phenformin, and galegine; the thiazolidi-
nedione troglitazone; the barbiturate phenobarbital; and the
phytochemicals resveratrol, quercetin, and berberine. These
agents caused phosphorylation and activation of AMPK only in
WT and not in RG cells, inhibited cellular oxygen uptake, and
(apart from metformin) significantly increased ADP:ATP ratios.
Except for phenobarbital and galegine, most of these agents
have already been reported to inhibit the function of isolated
mitochondria. Thus, metformin, phenformin, thiazolidinediones,
and berberine inhibit respiratory chain complex I (El-Mir et al.,
2000; Owen et al., 2000; Brunmair et al., 2004; Turner et al.,
2008), while resveratrol and quercetin inhibit the ATP synthase
(Zheng and Ramirez, 2000). After maximal inhibition of the respi-
ratory chain, oxygen uptake should not be stimulated by the
uncoupler DNP, and this was the case for metformin, phenfor-
min, galegine, troglitazone, phenobarbital, and berberine. Con-
versely, the reduced oxygen uptake caused by drugs that inhibit
the ATP synthase should be increased by DNP (which uncouples
the respiratory chain from ATP synthesis), and this was observed
with oligomycin and quercetin, and to a lesser extent with
resveratrol.
Although quercetin has been found to inhibit the ATP synthase
in isolated mitochondria (Zheng and Ramirez, 2000), our results
suggest that it is not acting solely via this mechanism in intact
cells. Quercetin produced a small but significant increase
(1.6-fold) in ADP:ATP at 100 mM (Figure 5B) and a much larger
increase at 300 mM (18-fold and 33-fold in WT and RG cells,
data not shown). However, any decrease in oxygen uptake was
undetectable at 100 mM and was quite modest (about 25%,
Figure 6B) at 300 mM. These results suggest that at these concen-
trations quercetinmayalso be depleting ATP byanother, unknown
mechanism. Although the effect was much smaller than in WT
cells, there was also a residual AMPK activation by quercetin in
RG cells, indicating an additional AMP-independent effect.ell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc. 559
Figure 6. Effect of Various Treatments on Oxygen Uptake and AMPK
Activity in HEK293 and H4IIE Cells
(A and B) Effects of different treatments on oxygen uptake in WT HEK293 cells.
Results are mean ± SEM, with n = from 4 to 10. Concentrations of the indicated
agent were as in Figure 4. Except in the case of metformin and sorbitol, oxygen
uptake was measured in the same well before treatment (basal), after treat-
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560 Cell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc.Although metformin did not produce significant increases in
ADP:ATP ratio, the fact that it caused phosphorylation and acti-
vation of AMPK in WT but not RG cells clearly shows that it was
acting by increasing cellular AMP. We (Hawley et al., 2002) and
others (Fryer et al., 2002) previously failed to detect a change
in AMP:ATP ratio in cells treated with metformin. However,
perfusion of intact rat heart with metformin was found to increase
AMP in concert with AMPK activation (Zhang et al., 2007). In that
study, AMP concentration was not measured in extracts but was
calculated from the intracellular concentrations of phosphocrea-
tine and ATP estimated by 31P-NMR, assuming that the creatine
kinase and adenylate kinase reactions were at equilibrium. AMP
is compartmentalized between mitochondria and the cytoplasm
and may not be evenly distributed even within the cytoplasm
(Dzeja and Terzic, 2003). The method used by Zhang et al.
(2007) may estimate changes in the relevant pool of AMP more
reliably than measurements in cell extracts. Our study demon-
strates that a failure to detect a change in the levels of adenine
nucleotides in a cell extract, whether in response to metformin
(Fryer et al., 2002; Hawley et al., 2002) or resveratrol (Suchan-
kova et al., 2009), does not provide conclusive evidence that
the treatment is working via an AMP-independent mechanism.
Others have suggested more complex mechanisms by which
metformin, resveratrol, and quercetin activate AMPK. It has been
proposed that activation by metformin involves generation of
reactive nitrogen species and a cascade involving c-Src and
phosphatidylinositol 3-kinase (Zou et al., 2003), and/or by phos-
phorylation of LKB1 by protein kinase C-z, causing its transloca-
tion from the nucleus to the cytoplasm (Xie et al., 2008). It has
also been proposed that resveratrol and quercetin activate the
NAD-dependent histone deacetylase SIRT1, triggering deacety-
lation of LKB1 and phosphorylation of AMPK (Suchankova et al.,
2009). However, many aspects of these hypotheses remain
unconfirmed: even whether resveratrol activates SIRT1 directly
(Howitz et al., 2003) has been challenged (Pacholec et al.,
2010). It has recently been proposed that its effects on SIRT1
in vivo may be secondary to AMPK activation (Canto et al.,
2009, 2010), and consistent with this, the metabolic effects of
dietary resveratrol are lost in AMPK knockout mice (Um et al.,ment for 1 hr, and after subsequent addition of DNP. Statistical significance
was assessed using repeated-measures ANOVA; differences between basal
and treatment: *p < 0.05; **p < 0.01; ***p < 0.001; differences between treat-
ment and treatment plus DNP: yp < 0.05; yyp < 0.01; yyyp < 0.001. In the case
of metformin and sorbitol, technical issues prevented a repeated-measures
design. Instead, oxygen uptake in treated wells (16 hr metformin, 1 hr sorbitol)
was compared with control wells on the same plate, although the effect of DNP
was compared in the treated well. Statistical significance of differences
between untreated and treated wells was by unpaired t test.
(C) Activation of AMPK (top), and phosphorylation of the AMPK target, ACC,
(bottom) in H4IIE cells treated for 1 hr with 3 mM metformin, 300 mM phenfor-
min, or 30 mM galegine with or without pretreatment (15 min) with 10 mM quin-
idine. Data are mean ± SD (n = 2). Statistical significance was assessed using
two-way ANOVA; significant differences between drug-treated samples and
controls are indicated: *p < 0.05, ***p < 0.001.
(D) Oxygen uptake in H4IIE cells treated without metformin (open circles) or
with 1 mM (filled triangles), 3 mM (open inverted triangles), or 10 mM metformin
(filled squares) for the times indicated. Data are mean ± SD (n = 15). Statistical
significance was assessed using two-way ANOVA; significant differences
between control and drug-treated samples at the same time point are indi-
cated: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 7. Effect of theCaMKK Inhibitor STO-609 onAMPKActivation
by A23187, Sorbitol, Berberine, and A769662; and Effect of A23187,
Sorbitol, and Berberine on Intracellular Ca2+
(A–D) WT or RG cells were incubated with the following: (A) A23817 (3 or
10 mM), (B) sorbitol (1.5 M), (C) berberine (100 mM), and (D) A769662 (300 mM),
with or without 10 mM STO-609 for 1 hr. AMPK was assayed as in Figure 2.
Results are expressed as a percentage of the average activity in control cells
as mean ± SD (n = 2). Statistical significance was assessed by two-way
ANOVA (significantly different from control without primary agent (***p < 0.001)
or without STO-609 (+p < 0.05, +++p < 0.001).
(E) Records of Fura-2 fluorescence ratio (F340/F380) against time illustrating the
effect of 10 mM A23187, 0.15 M sorbitol, or 30 mM berberine on cytoplasmic
Ca2+ concentration in individual WT cells. Each agent was added at 300 s
(arrow).
(F) Average F340/F380 values for the basal (B, prior to treatment), peak (P), and
sustained (S) phases of response to 10 mM A23187 and 0.15 M sorbitol in WT
and RG cells. Data are mean ± SD (n = from 3 to 7. Significance of differences
from basal was assessed by two-way ANOVA: *p < 0.05, ***p < 0.001.
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(Zheng and Ramirez, 2000) by binding to the g subunit (Gledhill
et al., 2007), and our results support the idea that it activates
AMPK via this mechanism.
A surprising finding was that metformin caused a rather severe
inhibition of the respiratory chain in HEK293 cells (Figure 6B), but
caused only a modest activation of AMPK without significant
changes in ADP:ATP. However, a key difference with the metfor-
min experiments was the 16 hr incubation rather than the 1 hr
used with all other treatments, a modification necessitated by
the slow uptake of metformin into HEK293 cells (Shu et al.,
2007). This prolonged incubation may give the cells more time
to adapt to inhibition of oxidative phosphorylation, perhaps by
upregulating glycolysis. The experiments in Figures 6 showCthat inhibition of the respiratory chain in H4IIE cells was almost
maximal after 2 hr, as was AMPK activation. In these cells,
AMPK activation by metformin was blocked by quinidine,
a competitive inhibitor of OCT1. Interestingly, AMPK activation
in response to phenformin or galegine was not blocked by quin-
idine, indicating that their cellular uptake is not dependent on the
transporter. This is also consistent with our findings that these
agents activated AMPK much more rapidly than metformin in
HEK293 cells.
Overall, perhaps the most striking finding to emerge from our
study was that many AMPK activators are inhibitors of mitochon-
drial function. Why should such a wide variety of xenobiotics
inhibit mitochondria? One explanation is that the respiratory
chain and ATP synthase are composed of several large, hydro-
phobic multiprotein complexes, potentially providing many bind-
ing sites where hydrophobic xenobiotics might inhibit their
function. Another interesting possibility is that many of the AMPK
activators are secondary plant metabolites and may have
evolved as inhibitors of mitochondrial function to render the
plants toxic to grazing animals or microbial pathogens. Interest-
ingly, one of the common English names of Galega officinalis
(from which galegine is derived) is goat’s rue, signifying that
the plant is poisonous to herbivores.
Our results also clarify the mechanisms of some other AMPK-
activating treatments. First, hydrogen peroxide caused activa-
tion and phosphorylation of AMPK in WT but not in RG cells,
increased the ADP:ATP ratio, and inhibited whole-cell oxygen
uptake with no effect of subsequent DNP addition. Thus,
although oxidative stress does activate AMPK (Choi et al., 2001;
Hwang et al., 2005), the target for reactive oxygen species may
not be AMPK itself but component(s) of the respiratory chain,
leading to a secondary effect on AMPK via increases in
AMP:ATP ratio. Second, our results are consistent with the idea
that 2-deoxyglucose acts by inhibiting glycolysis, because it
caused phosphorylation and activation of AMPK in WT but not
RG cells and increased cellular ADP:ATP ratios but did not affect
oxygen uptake. Third, osmotic stress using sorbitol appears to
activate AMPK by multiple mechanisms. While it caused activa-
tion of AMPK in RG cells, this was significantly less than that
observed in WT cells. It caused a significant increase in cellular
ADP:ATP ratio and a decrease in basal oxygen uptake, but it
also triggered intracellular Ca2+ release, and its effects were
partially blocked by STO-609. Taken together, these results
suggest that osmotic stress acts via two mechanisms, involving
increases in both AMP and Ca2+.
An important subsidiary finding of our study was that, although
the expression levels of the WT and R531G mutants of AMPK in
the stably transfected cells were identical, the RG mutant was
about twice as active when measured in the absence of AMP,
associated with a 2-fold higher basal Thr-172 phosphorylation
(Figure 1). While an increase in basal activity of the g2 mutations
has been previously proposed, this was either based on indirect
assays after expression in yeast (Arad et al., 2002) or on kinase
assays after transient transfection, which is complicated by
variable expression levels (Burwinkel et al., 2005). In the stably
transfected, isogenic cell lines used in this study, the size of
the effect could be quantified in a more reliable manner. The
RG mutant, despite its increased basal phosphorylation, was
further activated by treatments that increased cytoplasmicell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc. 561
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have shown previously that this mutation interferes with the
binding to the g2 subunit not only of the activating ligand,
AMP, but also of the inhibitory ligand, ATP (Scott et al., 2004).
This is consistent with structural studies of g1 showing that the
side chain of Arg-298 (equivalent to Arg-531 in g2) is directly
involved in binding of AMP and ATP to the exchangeable site
formed by CBS repeats 3 and 4 (Xiao et al., 2007). Since AMP
binding inhibits dephosphorylation of Thr-172, an interesting
possibility is that ATP binding might enhance it. According to
this model, the phosphorylation state of AMPK in unstressed
WT cells is low because the majority of the complexes have
ATP, rather than AMP, bound to the g subunit, thus promoting
dephosphorylation. However, due to reduced affinity for ATP,
AMPK in unstressed RG cells might be partially nucleotide-free,
causing enhanced net phosphorylation. Whatever the explana-
tion, the RG mutation causes both loss of function (failure to be
activated by AMP) and gain of function (increased basal activity).
The gain-of-function effect explains not only why the genetic
disorders in humans with R531G (or related mutations) are domi-
nant but also why they are associated with increased glucose
uptake and glycogen accumulation (Luptak et al., 2007).
A second subsidiary finding from our study was that, for most
of the pharmacological agents tested, the increases in ADP:ATP
ratio were larger in the WT than in the RG cells (Figure 5). One
possible explanation is that the high basal activity of AMPK in
the RG cells causes long-term adaptations that allow the cells
to better withstand the metabolic stresses imposed, although
we could not find any evidence that this involves increased mito-
chondrial biogenesis.
In summary, the use of WT and RG cells allows us to distin-
guish several different mechanisms by which AMPK can be acti-
vated, of which the first three cause indirect activation by
increasing cellular AMP: (1) inhibition of the respiratory chain
(biguanides, galegine, troglitazone, phenobarbital, berberine),
(2) inhibition of the mitochondrial ATP synthase (oligomycin,
resveratrol), (3) inhibition of glycolysis (2-deoxyglucose), (4)
increasing cytoplasmic Ca2+ (A23187), (5) intracellular conver-
sion into an AMP mimetic (AICAR), and (6) direct binding to
AMPK at a site distinct from the AMP site (A769662). Some treat-
ments, such as osmotic stress or quercetin, may work through
more than one of these mechanisms.
EXPERIMENTAL PROCEDURES
Materials and Proteins
STO-609 was from Tocris Bioscience, Bristol, UK. Phenformin, metformin,
H2O2, sorbitol, DNP, A23187, phenobarbital, quercetin, resveratrol, berberine,
and 2-deoxyglucose were from Sigma, Poole, UK. Oligomycin, troglitazone,
and AICAR were from CN Biosciences, Nottingham, UK. Zeocin and hygrom-
ycin B were from Invitrogen, Renfrew, UK. Galegine was a generous gift from
Brian Furman (Strathclyde Institute of Pharmacy and Biomedical Sciences
University of Strathclyde, Glasgow, UK). A769662 was synthesized as
described previously (Iyengar et al., 2005).
Antibodies
The antibody against the phosphorylated form of Thr-172 on the AMPK
a subunits was from New England Biolabs, Hitchin, UK. Antibodies against
the myc and FLAG epitopes were from Sigma, Poole, UK. Antibodies against
AMPK-g1 were from Abcam, Cambridge Science Park, Cambridge, UK. Anti-
bodies against AMPK-a1 and -a2 (Woods et al., 1996), AMPK b2 (Thornton562 Cell Metabolism 11, 554–565, June 9, 2010 ª2010 Elsevier Inc.et al., 1998), AMPK-g2 (Cheung et al., 2000), and pACC (Hawley et al., 2003)
were as described previously. Antibodies against AMPK-b1 were raised using
the peptide KTPRRDSSGGT (residues 18–28 of rat sequence) with an
N-terminal cysteine residue to allow coupling via the thiol to keyhole limpet
haemocyanin. The immunization schedule and affinity purification of the anti-
body on a phosphopeptide column was as previously described (Sugden
et al., 1999).
Plasmids
Full-length human g2 was amplified with primers designed to encode
a 50-BamHI site and a C-terminal FLAG tag followed by an XhoI site. The result-
ing PCR product was cloned into the pcDNA5/FRT plasmid (Invitrogen) to
create pcDND5/FRT/g2. Mutagenesis of the construct was performed using
the QuikChange Site-Directed Mutagenesis system (Stratagene). The plasmid,
POG44, expressing Flp recombinase was from Invitrogen.
Generation of Stable Cell Lines
HEK293 cells containing a single FRT site (Invitrogen) were transfected with
Lipofectamine 2000 (Invitrogen) using the plasmids POG44 and pcDND5/
FRT/g2 at a ratio of 9:1. Fresh medium was added to the cells 24 hr after trans-
fection, and media containing 200 mg/ml hygromycin B was added 48 hr after
transfection. The medium was replaced every 3 days until foci could be iden-
tified, and individual foci were then selected and expanded. The expression of
FLAG-tagged g2 was checked using immunofluorescence microscopy and
Western blotting using anti-FLAG antibodies.
Cell Culture
Flp-In HEK293 cells (Invitrogen) containing a single FRT site were cultured in
Dulbecco’s modified Eagles’s medium (DMEM) containing 4.5 g/L glucose,
10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml strepto-
mycin, and 100 mg/ml zeocin. After transfection, Flp-In HEK293 cells stably
expressing either WT or R531G AMPK-g2 were cultured as above except
that zeocin was replaced by 200 mg/ml hygromycin B. After various treatments
as indicated in the figure legends, cells were rinsed rapidly with ice-cold phos-
phate-buffered saline to remove the medium and then lysed in situ using 0.3 ml
of ice-cold lysis buffer (50 mM Tris/HCl [pH 7.2], 1 mM EGTA, 1 mM EDTA,
50 mM NaF, 1 mM Na pyrophosphate, 1% [w/v] Triton X-100, 0.1 mM phenyl-
methane sulphonyl fluoride [PMSF], 1 mM DTT, 0.1 mM benzamidine, and
5 mg/ml soybean trypsin inhibitor). The lysates were centrifuged (4C,
10 min, 21,000 3 g) and the supernatants frozen for later analysis. H4IIE cells
(provided by Dr. Calum Sutherland, University of Dundee) were grown as for
HEK293 cells except that FBS was at 5% (v/v).
Immunoprecipitate Kinase Assays of AMPK
Lysates containing stably expressed, recombinant FLAG-tagged g2 (either WT
or R531G) were immunoprecipitated from HEK293 cell lysates (90 mg protein)
by incubation at 4C for 2 hr on a roller mixer with 9 ml of EZview Red anti-FLAG
M2 affinity gel (Sigma). After extensive washing, the immunoprecipitates were
assayed for AMPK activity as described (Towler et al., 2008) using the AMARA
peptide (Dale et al., 1995) as substrate, except for Figure 1C, where the SAMS
peptide (Davies et al., 1989) was used.
Estimation of Cellular ADP:ATP Ratio
Culture medium was quickly aspirated from cells grown on 6 cm culture
dishes, and cells were washed with 1 ml of ice-cold PBS. After rapid aspiration
of PBS, a minimal volume of ice-cold 5% perchloric acid was added and the
samples vortexed to ensure complete lysis. After centrifugation (14,000 rpm,
4C, 3 min) to remove acid-insoluble material, the supernatant was extracted
with two washes of an equal volume of 1:1 tri-n-octylamine and 1,1,2-trichlor-
otrifluoroethane. The nucleotides remaining in the aqueous phase were then
separated by capillary electrophoresis with on-column isotachophoretic
concentration, using run buffers consisting of 50 mM Na phosphate and
50 mM NaCl (pH 5.2; leading buffer) and 100 mM MES/Tris (pH 5.2; tailing
buffer). To each buffer was added 0.2% hydroxyethylcellulose to decrease
electro-osmotic flow. Nucleotide peaks were detected by UV absorbance at
260 nM and integrated using System Gold software (Beckman). Nucleotide
ratios were calculated from peak areas after correction for retention times.
Identification of peaks as ATP, ADP, and AMP were confirmed by additional
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individual peaks.
Calcium Imaging
HEK293 cells were plated onto sterile 35 mm glass-bottomed tissue culture
dishes (FluoroDish; World Precision Instruments, FL, USA) that were prepared
by coating the glass base of each dish with 1 ml of 100 mg/ml poly-D-lysine
hydrobromide (PDL) for 5 min. Cells were incubated for 30 min with 5 mM
Fura-2-AM in PSS of the following composition (mM): 130 NaCl, 5.2 KCl,
1 MgCl2, 1.7 CaCl2, 10 glucose, and 10 HEPES (pH 7.4). After washing with
Fura-2 free PSS for at least 30 min prior to experimentation, culture dishes
were placed on a Leica DMIRBE inverted microscope. Cytoplasmic Ca2+ con-
centration was then reported by the Fura-2 fluorescence ratio (F340/F380 exci-
tation; emission 510 nm) as previously described (Calcraft et al., 2009). Emitted
fluorescence was recorded at 22C with a sampling frequency of 0.1 Hz, using
a Hamamatsu 4880 CCD camera via a Zeiss Fluar 403 , 1.3 n.a. oil immersion
lens, and Leica DMIRBE microscope. Background subtraction was performed
online. Analysis was via Openlab imaging software (Perkin-Elmer, UK).
Other Analytical Procedures
SDS/PAGE was performed using precast Bis-Tris 4%–12% gradient poly-
acrylamide gels in the MOPS buffer system (Invitrogen). Proteins were trans-
ferred to nitrocellulose membranes (Bio-Rad) using the Xcell II Blot Module
(Invitrogen). Membranes were blocked for 1 hr in Odyssey blocking buffer
(Li-Cor biosciences, Cambridge, UK). The membranes were probed with
appropriate antibody (0.1–1 mg/ml) Odyssey blocking buffer. Detection was
performed using secondary antibody (1 mg/ml) coupled to IR 680 or IR
800 dye and the membranes scanned using the Li-Cor Odyssey IR imager.
Protein concentrations were determined by Coomassie blue binding
(Bradford, 1976) with BSA as standard.
Measurement of Whole-Cell Oxygen Uptake
Oxygen uptake was measured in 24 well plates using the Seahorse XF24
Extracellular Flux Analyzer. Cells were incubated at a density of about 106 cells
per well in unbuffered medium (pH 7.4): 8.3 g/L DMEM base, 200 mM Gluta-
Max-1, 100 mM Na pyruvate, 25 mM glucose, 32 mM NaCl, and 40 mM Phenol
Red. Oxygen consumption rates were continuously measured as described
previously (Wu et al., 2007).
Statistical Analysis
Statistical analyses, as detailed in the figure legends, were performed using
GraphPad Prism 5 for Mac OSX.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results and one figure and
can be found with this article at doi:10.1016/j.cmet.2010.04.001.
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